Insider at

04

Insider transactions

05
0 buys (P) 0 sells (S) Net: $0 + 2 non-open-market transactions below last 12 months, based on the transactions shown below

Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted

No open-market trades on record; showing all filings.

DateTickerCodeSharesPriceValue Owned afterΔ ownA/Dvs now
Oct. 31, 2019 HBIO A 86,614 · · 86,614 Direct · Acquired (price as of 2026-10-05)
Oct. 31, 2019 HBIO A 39,286 · · 39,286 Direct · Acquired (price as of 2026-10-05)

P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding

Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.

Derivative holdings (Form 4 Table II) Options, RSUs and convertible securities reported on Form 4 Table II.

06
DateTickerSecurityUnderlying Exercise priceExpirationSharesA/D
Oct. 31, 2019 HBIO Stock option (right to buy) Common Stock, par value $0.01 per share (86,614) $2.80 Oct. 31, 2029 86,614 Acquired

Exercise/conversion price is blank when not applicable (e.g. RSUs).

Compensation (DEF 14A)

08

Matched by name from proxy statements (DEF 14A) — verify against the filing.

Fiscal yearSalaryBonusStock awards Option awardsNon-equity incentivePension changeOtherTotal
2019 $45,539 · · · · · · $274,576

Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.